Skip to main content
The University of Arizona Wordmark Line Logo White
Stories & Features Announcements Calendar Leadership Updates Event Planning Room Scheduling Café Bolo Directories IT Support Classroom Support Planning & Facilities
The University of Arizona Health Sciences | Home
Subscribe
Support
home home

Main navigation

  • Overview Senior Leadership Academic Leadership Executive Leadership Annual Report Mission, Values, History Support
  • Overview College of Health Sciences College of Medicine – Phoenix College of Medicine – Tucson College of Nursing Mel and Enid Zuckerman College of Public Health R. Ken Coit College of Pharmacy
  • Research Administration Research Awards and Grants
  • Clinical
  • Overview Community Engagement Alliance Corporate and Community Relations Health and Humanities Rural Health Community Events Student Engagement and Career Advancement
  • Overview Aegis Consortium All of Us Research Program Arizona Area Health Education Centers Arizona Simulation Technology & Education Center Asthma & Airway Disease Research Center Center for Accelerated Biomedical Innovation Center for Advanced Molecular & Immunological Therapies Center for Biomedical Informatics & Biostatistics Center for Disparities in Diabetes, Obesity & Metabolism Center for Innovation in Brain Science Center for Sleep, Circadian & Neuroscience Research Clinical & Translational Sciences Research Center Comprehensive Center for Pain & Addiction Health Sciences SensorLab One Health University of Arizona Cancer Center
  • All News Stories Videos The Healthy Dose Blog News Releases In The Media Media Resources Office of Communications
  1. Home
  2. Node

A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infec

Read more about A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infec

A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clin

Read more about A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clin

A Phase 3, Randomized, Open-label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-cell Lymphoma (DLB

Read more about A Phase 3, Randomized, Open-label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-cell Lymphoma (DLB

A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALT-100 in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

Read more about A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALT-100 in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Read more about A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Read more about A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
Subscribe to
The University of Arizona Health Sciences | Home

Health Sciences

  • About
  • Academics
  • Research
  • Centers and Programs
  • Clinical Care
  • Outreach
  • Initiatives

News

  • Stories
  • Healthy Dose Blog
  • News Releases
  • In The Media
  • Media Resources
  • Videos

Internal Resources

  • Stories & Features
  • Announcements
  • Calendar
  • Leadership Updates
  • Honors and Awards
  • Event Planning
  • Room Scheduling
  • Café Bolo
  • El Mirador Project
  • IT Support
  • Classroom Support
  • Planning and Facilities
  • Photo Galleries
  • Directories

Connect

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • X, formerly Twitter

We respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples. Today, Arizona is home to 22 federally recognized tribes, with Tucson being home to the O’odham and the Yaqui. The university strives to build sustainable relationships with sovereign Native Nations and Indigenous communities through education offerings, partnerships, and community service.


University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.